Multibagger Selection: DeepSeek's picks
DeepSeek picked INOD, UMAC, CAPR, NUAI, PDYN with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | DeepSeek |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | INOD | — | 76% | — | — |
| 2 | UMAC | — | 74% | — | — |
| 3 | CAPR | — | 70% | — | — |
| 4 | NUAI | — | 66% | — | — |
| 5 | PDYN | — | 62% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -1.52% | -0.85% | 1.28x | 0 |
| 1 month | -31.89% | -31.14% | 1.28x | 0 |
The model's market view
The current environment for small and mid-cap multibagger candidates is shaped by three forces:
(1) an AI infrastructure and data-engineering supercycle that is disproportionately benefiting smaller, specialized contractors with verifiable revenue acceleration;
(2) a US defense-technology procurement ramp, including drone dominance programs and national-security AI spending, that is creating a new cohort of emerging defense suppliers; and
(3) elevated interest rates above 5% that punish cash-burning companies but reward those with clear paths to profitability and strong balance sheets. The best multibagger candidates are companies with explosive sequential revenue growth, expanding gross margins, a specific time-bound catalyst, and enough liquidity to survive 12 months without highly dilutive emergency financing.
Why each pick
INOD
Innodata is a data-engineering company that supplies high-quality training, evaluation and alignment data to frontier AI model developers. The operating inflection is dramatic: Q1 2026 revenue was $90.1 million (+54% YoY, +24% QoQ), and Q2 2026 revenue reached $92.1 million (+58% YoY), marking the 12th consecutive quarter of year-over-year revenue growth. Adjusted gross margin expanded from 40% a year ago to 49% in Q2 2026. Adjusted EBITDA jumped 91.6% YoY to $25.36 million. The company raised its full-year 2026 revenue growth forecast to at least 40%. Customer diversification improved materially, with the largest customer falling from 56% to 37% of revenue, while Big Tech customers rose from 17% to 34%. The stock has a consensus Strong Buy rating from four analysts with an average price target of $122.75, and BWS Financial reaffirmed a $140 target on September 18, 2026. Risks include customer concentration (top customer still at 37%), the risk that AI-training data demand decelerates, and a rich valuation of approximately 45x forward EPS.
UMAC
Unusual Machines is a domestic drone-component manufacturer riding the US government's push for NDAA-compliant, reshored drone supply chains. The revenue inflection is extreme: Q1 2026 revenue was $8.1 million (+296% YoY), and Q2 2026 revenue surged 687% YoY to $16.7 million, more than doubling sequentially and surpassing the Zacks Consensus Estimate by 74.6%. B2B revenue jumped to $7.3 million from just $34,030 in the prior-year quarter, and retail now accounts for only 6% of revenue, confirming a successful shift to enterprise and defense customers. Gross margin was 34.7% in Q2 2026, improving sequentially but below the company's 40% target due to rapid scaling costs. The company has multiple US-made, NDAA-compliant products approved for the Blue UAS Framework, and management highlighted expectations for roughly 60,000 drones to be ordered in H2 2026 through the $1.1 billion Drone Dominance Gauntlet program. The stock has a Strong Buy consensus from 8 analysts with an average price target of $39. Risks include gross-margin compression during rapid scaling, a history of losses and negative free cash flow, and the possibility that drone procurement programs are delayed or awarded to competitors.
CAPR
Capricor Therapeutics is a clinical-stage biotechnology company with a Biologics License Application for Deramiocel under active FDA review for the treatment of Duchenne muscular dystrophy. The HOPE-3 Phase 3 trial met its primary endpoint and all Type I error-controlled secondary endpoints, and the PDUFA target action date is August 22, 2026. The company has approximately $279 million in cash, which is expected to support operations into Q4 2027, and it is eligible for a Priority Review Voucher upon approval, which is transferable and monetizable as non-dilutive capital. Analysts have responded positively: Piper Sandler upgraded to Overweight on September 1, 2026, and B. Riley upgraded to Buy on September 14, 2026, with a consensus average price target of $27-28.50. The stock recently traded down to ~$8.67, well below the analyst consensus, reflecting skepticism about the August PDUFA outcome. Risks include the binary nature of the FDA decision, the company's ongoing lawsuit against NS Pharma seeking rescission of a distribution agreement, and the fact that the PDUFA date has already passed, meaning the FDA could have issued a decision that is not yet reflected in the current price.
NUAI
New Era Energy & Digital is a small-cap neocloud and digital-infrastructure company that has executed a series of foundational shifts. The stock has surged over 60% in the past month after signing a 20-year power purchase agreement with Vistra subsidiary Luminant ET Services Company, which removes a major obstacle to securing hyperscaler tenants for its data-center facilities. The company has an option on a 7-gigawatt New Mexico site, and securing a hyperscaler lease would be the next major catalyst. The balance sheet is strong: approximately $84.8 million in cash and $270 million in undrawn credit, with minimal debt of approximately $15 million. Analyst coverage is thin but positive: Northland Capital Markets initiated coverage with an Outperform rating, and the consensus price target is $11, implying approximately 53% upside. Risks include the pre-revenue nature of the data-center business (TTM revenue of $900,915), the possibility that hyperscaler lease negotiations fail or are delayed, and the capital-intensive nature of data-center development.
PDYN
Palladyne AI is a small-cap autonomy-software company focused on defense applications. Revenue growth has been explosive: Q1 2026 revenue was $3.5 million (+107% YoY), and Q2 2026 revenue was approximately $5.8 million (+470% YoY, +63% QoQ). The company reaffirmed full-year 2026 revenue guidance of $24-27 million, which would represent growth of 357-415% over FY2025. The backlog is approximately $24 million, providing strong revenue visibility. Consolidated gross margin was approximately 29% in Q2 2026, reflecting manufacturing utilization below full capacity, with management guiding to H2 margin improvement. The company has $43.7 million in cash. The specific catalyst is a strategic partnership with Israel Aerospace Industries to manufacture, integrate, and market IAI's HARPY, HAROP, and Mini HARPY loitering munition systems to the US Department of War. Analyst coverage is positive: Northland Capital Markets initiated with Outperform, Lake Street initiated with Buy, and the consensus price target is $10.75-11.25, implying approximately 98-107% upside. Risks include customer concentration, the small absolute revenue base, reliance on a partnership that is not yet generating material revenue, and the possibility that defense procurement timelines slip.
Other models on the same run
| Model | Picks |
|---|---|
| GPT-5.6 Sol | LUNR, RCAT, POET, ONDS, AEVA |
| Claude Opus 5 | ICHR, OUST, RUM, USAR, EMAT |
| Muse Spark 1.1 | KPLT, INDP, BNC, CHPT, SWVL |
| Gemini 1.5 Pro | RCAT, LUNR, RDW, SMR, ENVX |
| Grok 4.5 | VRDN, REPL, NRIX, AEVA, SERV |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.